-
Price Momentum
PFE is trading in the middle of its 52-week range and above its 200-day simple moving average.
-
Price change
The price of PFE shares has increased $1.11 since the market last closed. This is a 4.57% rise.
-
Opened at $24.50.
The stock opened $0.11 higher than its previous close.
Key terms
About PFE
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
-
Market cap: $138.90B
A market capitalization between $10 billion and $200 billion places PFE in the large capitalization category.
Key terms
Ad Feedback
Smart score
Latest PFE news
Today
10:25am ET
Pfizer call volume above normal and directionally bullish
Today
7:36am ET
Cautious Optimism: Pfizer’s Strategic Initiatives and Clinical Trials Amidst Oncology Competition
Yesterday
12:06pm ET
Midday Fly By: Insurers slip as Senate spending bill lacks ACA extension
Yesterday
11:40am ET
FDA approves generic version of Pfizer’s Premarin
Yesterday
11:40am ET
HHS removing ‘misleading’ FDA warnings on hormone replacement therapy
Yesterday
10:01am ET
Viking Therapeutics Stock (VKTX) Jumps on Obesity Drug. The Next Big Pharma Target?
Yesterday
9:06am ET
Video: Health insurers weighed on by shutdown news, Trump post
Yesterday
8:55am ET
Morning Movers: Monday.com sinks following third quarter results
Yesterday
7:46am ET
Nurix Therapeutics appoints Dansey to board of directors
Yesterday
7:35am ET
Novo Nordisk Stock (NVO) Rises on Plan to Pursue Other Obesity Deals after Metsera Loss
Nov 09, 2025
9:06pm ET
Pfizer’s Strategic Acquisition of Metsera: Balancing Opportunities and Risks in the Obesity Market
Nov 09, 2025
3:55pm ET
Novo continues to look for opportunities in obesity, diabetes, Bloomberg says
Nov 09, 2025
5:29am ET
Pfizer Clinches $10 Billion Metsera Deal as Novo Nordisk Loses Weight-Loss Drug Battle
Nov 08, 2025
10:02am ET
Pfizer’s Earnings Shine Amid Analyst Caution
Nov 08, 2025
9:10am ET
Metsera enters deal to be acquired by Pfizer for up to $86.25 per share
Nov 06, 2025
11:05am ET
Novo Nordisk again raises bid for Metsera, Endpoints News reports
Nov 06, 2025
6:47am ET
Pfizer’s Strong Q3 Performance Overshadowed by Pipeline Delays and Patent Concerns: Hold Rating Maintained
Nov 05, 2025
6:35pm ET
Pfizer matches Novo Nordisk’s offer for Metsera, FT reports
Nov 05, 2025
5:45pm ET
Pfizer plans to sweeten offer for Metsera, WSJ reports
Nov 05, 2025
5:15pm ET
Pfizer says ‘we remain confident in the merits of our claims’ against Metsera
Nov 05, 2025
4:07pm ET
Novo Nordisk tells STAT Metsera deal structure ‘consistent with antitrust laws’
Nov 05, 2025
2:50pm ET
Metsera says will accept superior bids until closing, Bloomberg reports
Nov 05, 2025
2:30pm ET
Metsera falls after FTC raises filing concerns over Novo bid
Nov 05, 2025
12:41pm ET
3 Best Dividend Aristocrat Stocks to Buy Now, 11/05/2025
Nov 05, 2025
11:49am ET
Novo Nordisk Stock (NVO) Falls after Medicare Price Deal and Q3 Earnings Miss
Nov 05, 2025
10:46am ET
Pfizer (PFE) Gets a Hold from Cantor Fitzgerald
Nov 05, 2025
9:20am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Nov 05, 2025
9:10am ET
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE) and Rhythm Pharmaceuticals (RYTM)
Nov 05, 2025
8:15am ET
Pfizer’s Strong Performance and Strategic Positioning Justify Buy Rating Amidst Market Challenges
Nov 05, 2025
5:46am ET
NVO Earnings: Novo Nordisk Cuts Guidance amid Rising Weight Loss Drug Competition
Nov 05, 2025
3:39am ET
Google (GOOGL) Moves Closer to $32 Billion Wiz Deal after U.S. Review Ends
Jun 18, 2025
10:06am ET
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board Of Directors For Breach of Fiduciary Duties (PFE)
Jun 09, 2025
10:06am ET
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board Of Directors For Breach of Fiduciary Duties (PFE)
Jun 05, 2025
2:03pm ET
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board of Directors for Breach of Fiduciary Duties (PFE)
Mar 06, 2025
11:44am ET
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board Of Directors For Breach of Fiduciary Duties (PFE)
Mar 03, 2025
2:36am ET
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board Of Directors For Breach of Fiduciary Duties (PFE)
Feb 27, 2025
2:36am ET
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board Of Directors For Breach of Fiduciary Duties (PFE)
Feb 26, 2025
2:06am ET
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board Of Directors For Breach of Fiduciary Duties (PFE)
Feb 20, 2025
2:06am ET
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board of Directors for Breach of Fiduciary Duties (PFE)
Feb 17, 2025
3:33pm ET
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board Of Directors For Breach of Fiduciary Duties (PFE)
Feb 13, 2025
8:45am ET
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board Of Directors For Breach of Fiduciary Duties (PFE)
Nov 09, 2022
3:04pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pfizer Inc. - PFE
Nov 01, 2022
7:35pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pfizer Inc. - PFE
Oct 28, 2022
11:18am ET
INVESTIGATION NOTICE: The Schall Law Firm Announces It Is Investigating Claims Against Pfizer Inc. and Encourages Investors with Losses to Contact the Firm
May 11, 2022
10:08am ET
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Biohaven Pharmaceutical Holding Co. Ltd. Buyout
PFE Financials
-
Total revenue: $63.63B (1Y), $16.65B (Q3)
Total Revenue increased 8.77% since last year and increased 13.66% since last quarter.
-
Net income: $8.02B (1Y), $3.54B (Q3)
Net Income increased 276.0% since last year and increased 22.74% since last quarter.
-
Earnings per share: $1.41 (1Y), $0.62 (Q3)
EPS increased 274.7% since last year and increased 22.57% since last quarter.
Key terms
Ad Feedback
PFE Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
PFE Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
-
How competitors are chosen
PFE's competitors are included in the Health Technology sector and Pharmaceuticals: Major group
-
Market cap: $138.90B
A market capitalization between $10 billion and $200 billion places PFE in the large capitalization category.
